Han Witjes

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

Kathryn H. Brown, Craig Comisar, Han Witjes et al. · British Journal of Clinical Pharmacology · 2016 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials

Georg Griesinger, Bernadette Mannaerts, Claus Yding Andersen et al. · Fertility and Sterility · 2013 · 142 citations · Full text

Medicine, Gynecology, Obstetrics +15

Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment

A. Nyboe Andersen, Han Witjes, K. Gordon et al. · Human Reproduction · 2011 · 134 citations · Full text

Medicine, Endocrinology, Gynecology +17

Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization

R. Boostanfar, B.S. Shapiro, Michaël Lévy et al. · Fertility and Sterility · 2015 · 63 citations

Veterinary Medicine, Gynecology, Obstetrics +14

Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol

F. J. Broekmans, Paul E. Verweij, Marinus J.C. Eijkemans et al. · Human Reproduction · 2014 · 53 citations · Full text

Medicine, Endocrinology, Gynecology +17